Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.54 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418462 | 0.94 | ESR2 (0.59) | LTA4HNR5A1APPLMNACYP1A2 | |
| SCHEMBL9149725 | 0.90 | ALOX15 (0.50) | LTA4HNR5A1APPLMNACYP1A2 | |
| SCHEMBL3589633 | 0.87 | NQO1 (0.50) | LTA4HAPP | |
| SCHEMBL25124165 | 0.87 | ESR1 (0.57) | LTA4HNR5A1LMNACYP1A2SLC6A2 | |
| SCHEMBL14227001 | 0.85 | PKM (0.66) | LTA4HLMNAKMT2A | |
| SCHEMBL8452874 | 0.85 | LTA4H (0.56) | LTA4HNR5A1APPLMNACYP1A2 | |
| SCHEMBL4599599 | 0.83 | LTA4H (0.48) | LTA4HNR5A1APPLMNACYP1A2 | |
| SCHEMBL14514637 | 0.80 | CA1 (0.58) | APP | |
| SCHEMBL197283 | 0.80 | FYN (0.45) | CYP1A2CYP2C19ESR2 | |
| SCHEMBL12926336 | 0.80 | MMP2 (0.51) | LTA4HCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20250215010-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-07-03 | — | — | US | disclosed |
| WO-2025096495-A1 | ARYL FLUOROSULFATE-BASED INHIBITORS AS NOVEL ANTITUBERCULAR AGENTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119923399-A | Useful as matrix metalloproteinase inhibitors diazabicyclooctane derivatives of (a) | 瓦萨治疗有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4499647-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | Vasa Therapeutics Spolka Z Orgraniczona Odpowiedzialnoscia (PL) | 2025-02-05 | — | — | EP | disclosed |
| CN-114450284-B | 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023187670-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | VASA THERAPEUTICS SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2023-10-05 | — | — | WO | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
| US-6534524-B1 | Antiproliferative agents, including axitinib | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6531491-B1 | Methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, | AGOURON PHARAMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1218348-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001002369-A2 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5932196-A | DEOXYARBUTIN DERIVATIVES, STORAGE STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5250690-A | Selective killing of grassy weeds | DOWELANCO (US) | 1993-10-05 | — | — | US | disclosed |
| US-4968343-A | GRASSY WEEDS IN PRESENCE OF CORN PLANTS | THE DOW CHEMICAL COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0205821-A1 | Haloalkoxy anilide derivatives of 2-(4-heterocyclic oxyphenoxy)-alkanoic acids and their use as herbicides | THE DOW CHEMICAL COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
| CN-86103114-A | The halogenated alkoxy benzene of 2-(4-heterocyclic oxy group phenoxy group) alkanoic acid is for the preparation of amide derivatives and as herbicide applications | — | 1986-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | LTA4H 2924/4885NR5A1 1753/4885APP 2058/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | LTA4H 1008/4885NR5A1 430/4885APP 2733/4885 |
| US-20250215010-A1 | DIAZABICYCLOOCTANE DERIVATIVES USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP9, MMP8 | LTA4H 603/4885NR5A1 1965/4885APP 4612/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | LTA4H 4799/4885NR5A1 2929/4885APP 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.